Tirzepatide: GIP/GLP-1 Mechanism, SURMOUNT Clinical Data & Semaglutide Comparison

Tirzepatide is a single molecule that simultaneously activates the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism makes it a "twincretin" and explains the interest it attracts in the metabolic literature. GIP agonism additionally affects adipose tissue and may improve insulin sensitivity. For a detailed comparison, see Semaglutide vs Tirzepatide.

In approved clinical-trial and label contexts, Tirzepatide is presented with gradual titration so that tolerability and safety profile can be assessed. This literature structure does not constitute instructions for use or a personal recommendation. For research math, peptide reconstitution and concentration calculations, use the Peptide Calculator.

The SURMOUNT programme forms the basis of the Tirzepatide clinical data for obesity and metabolic endpoints. SURMOUNT-1, SURMOUNT-2 and SURMOUNT-5 publish results in specific populations and trial designs. These data are literature context — not a promise of outcome or therapeutic guidance. For how evidence is weighted, see the evidence framework.

The most common adverse events in the SURMOUNT trials were gastrointestinal: nausea (30.5% vs 15.4% placebo), diarrhoea (22.8%), vomiting (16%). These were mostly mild to moderate and occurred primarily during the escalation phase. Rarer: pancreatitis, cholecystitis. Like all GLP-1 agonists, it carries a black box warning for thyroid C-cell tumours (observed in rodents). For an educational review of side effects, see Peptide Side Effects.

Retatrutide (a triple agonist) shows strong Phase 3 metabolic endpoints but remains investigational. Tirzepatide is among the molecules with the strongest approved data to date. For a comparison, see Retatrutide vs Tirzepatide.